SIRT3 and neoplasm: On the other hand, SIRT3 expression is also found be increased in oral cancer, node-positive breast cancer, esophageal cancer, and thyroid carcinomas; and the increased SIRT3 is associated with higher malignant phenotype and downregulation of SIRT3 enhances tumor sensitivity to anti-cancer treatment [19–23].